Gaps in US Psychedelic Policy and How to Close Them
Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg, David B. Yaden
JAMA Health Forum November 7, 2025 DOI: 10.1001/jamahealthforum.2025.4928 via OpenAlex
Summary
This viewpoint outlines strategies for addressing policy gaps that would arise if the US Food and Drug Administration approves psychedelics for treating mental health and substance use conditions. It discusses regulatory, clinical, and public health considerations necessary to integrate these therapies into practice.
Study at a glance
| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Mental health Government linguistics Public policy Action physics |
| Citations | 4 |
| Key finding | Policy gaps surrounding the use of psychedelics for mental health and substance use conditions need to be addressed before and after potential FDA approval. |
Abstract
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.